JP2009530416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530416A5 JP2009530416A5 JP2009501679A JP2009501679A JP2009530416A5 JP 2009530416 A5 JP2009530416 A5 JP 2009530416A5 JP 2009501679 A JP2009501679 A JP 2009501679A JP 2009501679 A JP2009501679 A JP 2009501679A JP 2009530416 A5 JP2009530416 A5 JP 2009530416A5
- Authority
- JP
- Japan
- Prior art keywords
- solvent
- mixture
- drug
- volatile solvent
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 114
- 239000003814 drug Substances 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 35
- 229920000642 polymer Polymers 0.000 claims description 29
- 239000007962 solid dispersion Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims 94
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 57
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 41
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 30
- 229960000583 acetic acid Drugs 0.000 claims 16
- 239000012362 glacial acetic acid Substances 0.000 claims 16
- 208000005176 Hepatitis C Diseases 0.000 claims 12
- 239000003443 antiviral agent Substances 0.000 claims 12
- -1 anti-thyroid Substances 0.000 claims 11
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 9
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 8
- 229920003169 water-soluble polymer Polymers 0.000 claims 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 6
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 6
- 235000004626 essential fatty acids Nutrition 0.000 claims 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 4
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 4
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 3
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims 3
- 229930003427 Vitamin E Natural products 0.000 claims 3
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims 3
- 229940035676 analgesics Drugs 0.000 claims 3
- 239000000730 antalgic agent Substances 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 230000003276 anti-hypertensive effect Effects 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
- 230000000078 anti-malarial effect Effects 0.000 claims 3
- 230000002460 anti-migrenic effect Effects 0.000 claims 3
- 230000001022 anti-muscarinic effect Effects 0.000 claims 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims 3
- 239000000883 anti-obesity agent Substances 0.000 claims 3
- 229940124605 anti-osteoporosis drug Drugs 0.000 claims 3
- 230000000648 anti-parkinson Effects 0.000 claims 3
- 230000000842 anti-protozoal effect Effects 0.000 claims 3
- 230000003208 anti-thyroid effect Effects 0.000 claims 3
- 239000003416 antiarrhythmic agent Substances 0.000 claims 3
- 239000003146 anticoagulant agent Substances 0.000 claims 3
- 229940127219 anticoagulant drug Drugs 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 3
- 239000000935 antidepressant agent Substances 0.000 claims 3
- 229940005513 antidepressants Drugs 0.000 claims 3
- 239000003472 antidiabetic agent Substances 0.000 claims 3
- 229940125708 antidiabetic agent Drugs 0.000 claims 3
- 239000003429 antifungal agent Substances 0.000 claims 3
- 229940121375 antifungal agent Drugs 0.000 claims 3
- 229960002708 antigout preparations Drugs 0.000 claims 3
- 239000000739 antihistaminic agent Substances 0.000 claims 3
- 239000003430 antimalarial agent Substances 0.000 claims 3
- 229940034982 antineoplastic agent Drugs 0.000 claims 3
- 239000003096 antiparasitic agent Substances 0.000 claims 3
- 229940125687 antiparasitic agent Drugs 0.000 claims 3
- 239000000939 antiparkinson agent Substances 0.000 claims 3
- 239000003904 antiprotozoal agent Substances 0.000 claims 3
- 229940043671 antithyroid preparations Drugs 0.000 claims 3
- 239000002249 anxiolytic agent Substances 0.000 claims 3
- 230000000949 anxiolytic effect Effects 0.000 claims 3
- 239000002876 beta blocker Substances 0.000 claims 3
- 229940097320 beta blocking agent Drugs 0.000 claims 3
- 239000002475 cognitive enhancer Substances 0.000 claims 3
- 239000003246 corticosteroid Substances 0.000 claims 3
- 229940111134 coxibs Drugs 0.000 claims 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 3
- 239000002934 diuretic Substances 0.000 claims 3
- 230000001882 diuretic effect Effects 0.000 claims 3
- 239000008157 edible vegetable oil Substances 0.000 claims 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 239000003163 gonadal steroid hormone Substances 0.000 claims 3
- 230000000147 hypnotic effect Effects 0.000 claims 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims 3
- 230000001861 immunosuppressant effect Effects 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 201000001881 impotence Diseases 0.000 claims 3
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 3
- 229940041033 macrolides Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229940035363 muscle relaxants Drugs 0.000 claims 3
- 239000003158 myorelaxant agent Substances 0.000 claims 3
- 239000003176 neuroleptic agent Substances 0.000 claims 3
- 230000000701 neuroleptic effect Effects 0.000 claims 3
- 235000015097 nutrients Nutrition 0.000 claims 3
- 239000000014 opioid analgesic Substances 0.000 claims 3
- 229940005483 opioid analgesics Drugs 0.000 claims 3
- 239000000932 sedative agent Substances 0.000 claims 3
- 230000001624 sedative effect Effects 0.000 claims 3
- 229940126586 small molecule drug Drugs 0.000 claims 3
- 239000000021 stimulant Substances 0.000 claims 3
- 235000019165 vitamin E Nutrition 0.000 claims 3
- 229940046009 vitamin E Drugs 0.000 claims 3
- 239000011709 vitamin E Substances 0.000 claims 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 229940124091 Keratolytic Drugs 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 230000003257 anti-anginal effect Effects 0.000 claims 2
- 230000003177 cardiotonic effect Effects 0.000 claims 2
- 229920002301 cellulose acetate Polymers 0.000 claims 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 2
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 229920006037 cross link polymer Polymers 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 230000000762 glandular Effects 0.000 claims 2
- 230000001530 keratinolytic effect Effects 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 235000010981 methylcellulose Nutrition 0.000 claims 2
- 229960002900 methylcellulose Drugs 0.000 claims 2
- 229920000193 polymethacrylate Polymers 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 125000005591 trimellitate group Chemical group 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 239000004004 anti-anginal agent Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000004041 inotropic agent Substances 0.000 claims 1
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 claims 1
- 239000003410 keratolytic agent Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78427506P | 2006-03-20 | 2006-03-20 | |
| US87169206P | 2006-12-22 | 2006-12-22 | |
| PCT/US2007/064294 WO2007109605A2 (en) | 2006-03-20 | 2007-03-19 | Pharmaceutical compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013240174A Division JP2014037435A (ja) | 2006-03-20 | 2013-11-20 | 医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009530416A JP2009530416A (ja) | 2009-08-27 |
| JP2009530416A5 true JP2009530416A5 (enExample) | 2010-05-06 |
Family
ID=38523222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009501679A Withdrawn JP2009530416A (ja) | 2006-03-20 | 2007-03-19 | 医薬組成物 |
| JP2013240174A Pending JP2014037435A (ja) | 2006-03-20 | 2013-11-20 | 医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013240174A Pending JP2014037435A (ja) | 2006-03-20 | 2013-11-20 | 医薬組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20070218012A1 (enExample) |
| EP (1) | EP2001497A4 (enExample) |
| JP (2) | JP2009530416A (enExample) |
| KR (2) | KR20140107691A (enExample) |
| CN (1) | CN103272234A (enExample) |
| AR (1) | AR063468A1 (enExample) |
| AU (2) | AU2007226984B2 (enExample) |
| BR (1) | BRPI0708957A2 (enExample) |
| CA (1) | CA2646335A1 (enExample) |
| EA (1) | EA018811B1 (enExample) |
| EC (1) | ECSP088759A (enExample) |
| GE (1) | GEP20125378B (enExample) |
| IL (1) | IL194176A (enExample) |
| MX (1) | MX2008011976A (enExample) |
| NO (1) | NO20084334L (enExample) |
| NZ (1) | NZ571934A (enExample) |
| PE (1) | PE20080170A1 (enExample) |
| RS (1) | RS20090406A (enExample) |
| SG (1) | SG170087A1 (enExample) |
| TW (2) | TW201414469A (enExample) |
| UY (1) | UY30225A1 (enExample) |
| WO (1) | WO2007109605A2 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA79749C2 (en) | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| TWI359147B (en) | 2003-09-05 | 2012-03-01 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv n |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| AU2007217355B2 (en) | 2006-02-27 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same |
| EP2194039A1 (en) | 2006-03-16 | 2010-06-09 | Vertex Pharmceuticals Incorporated | Process for preparing optically enriched compounds |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| ES2882684T3 (es) | 2006-04-07 | 2021-12-02 | Vertex Pharma | Preparación de moduladores de transportadores del casete de unión a ATP |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| MX2009006806A (es) * | 2006-12-22 | 2009-08-27 | Vertex Pharma | Secado por rocio fluidizado. |
| CA2679312A1 (en) | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| CN101903392A (zh) | 2007-02-27 | 2010-12-01 | 弗特克斯药品有限公司 | 丝氨酸蛋白酶的抑制剂 |
| WO2009032198A1 (en) | 2007-08-30 | 2009-03-12 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| AU2009226019C1 (en) | 2008-03-20 | 2014-02-20 | Virun, Inc. | Emulsions including a PEG-derivative of tocopherol |
| CN103190631B (zh) | 2008-03-20 | 2016-01-20 | 维尔恩公司 | 非水性预乳液组合物及制备包含植物甾醇的饮料的方法 |
| EP2396028A2 (en) | 2009-02-12 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir |
| TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| CN105832678A (zh) | 2009-05-27 | 2016-08-10 | 株式会社三养生物制药 | 生物利用度提高的包含难溶性药物的微球及其制备方法 |
| EP2470019A4 (en) | 2009-08-25 | 2013-03-13 | Cardiokine Biopharma Llc | COMPOSITIONS FOR THE ADMINISTRATION OF NON-SOLUBLE AGENTS |
| WO2011094489A1 (en) | 2010-01-29 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Therapies for treating hepatitis c virus infection |
| CN103037708B (zh) * | 2010-03-23 | 2015-05-20 | 维尔恩公司 | 含有蔗糖脂肪酸酯的纳米乳液 |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| ES2845449T3 (es) * | 2010-03-25 | 2021-07-26 | Vertex Pharma | Dispersión sólida de forma amorfa de (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluoro-2(1-hidroxi-2-metilpropan-2-il)-1h-indol-5il)-ciclopropanocarboxamida |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| WO2011162802A1 (en) | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
| CN102293734A (zh) * | 2010-06-25 | 2011-12-28 | 江苏恒瑞医药股份有限公司 | 托伐普坦固体分散体及其制备方法 |
| AR082215A1 (es) | 2010-07-14 | 2012-11-21 | Vertex Pharma | Composicion farmaceutica agradable al paladar |
| CA2815416A1 (en) | 2010-10-21 | 2012-04-26 | Vertex Pharmaceuticals Incorporated | Biomarkers for hcv infected patients |
| WO2012063246A1 (en) * | 2010-11-11 | 2012-05-18 | Mapi Pharma Ltd. | Amorphous form of lurasidone hydrochloride |
| WO2012109646A1 (en) | 2011-02-11 | 2012-08-16 | Vertex Pharmaceuticals Incorporated | Treatment of hcv in hiv infection patients |
| US8981095B2 (en) | 2011-07-28 | 2015-03-17 | Mapi Pharma Ltd. | Intermediate compounds and process for the preparation of lurasidone and salts thereof |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| PT107894A (pt) | 2011-10-21 | 2014-10-31 | Abbvie Inc | Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão. |
| GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| KR20130069484A (ko) * | 2011-12-15 | 2013-06-26 | 주식회사 삼양바이오팜 | 세레콕시브 함유 고체분산체 및 그 제조방법 |
| WO2013116339A1 (en) | 2012-01-31 | 2013-08-08 | Vertex Pharmaceuticals Incorporated | High potency formulations of vx-950 |
| WO2013120025A1 (en) | 2012-02-10 | 2013-08-15 | Virun, Inc. | Beverage compositions containing non-polar compounds |
| US9012496B2 (en) | 2012-07-16 | 2015-04-21 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
| WO2014015217A1 (en) | 2012-07-19 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Biomarkers for hcv infected patients |
| WO2014042945A1 (en) * | 2012-09-11 | 2014-03-20 | Bend Research, Inc. | Methods for making pharmaceutical solid dosage forms of spray-dried dispersions |
| EA028009B1 (ru) | 2013-01-22 | 2017-09-29 | Ф.Хоффманн-Ля Рош Аг | Фармацевтическая композиция с улучшенной биодоступностью |
| US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
| WO2015077273A1 (en) * | 2013-11-22 | 2015-05-28 | Merck Sharp & Dohme Corp. | Composition of a non-nucleoside reverse transcriptase inhibitor |
| KR20150112416A (ko) * | 2014-03-28 | 2015-10-07 | 주식회사 일화 | 세레콕시브 고체분산체 및 그 제조방법 |
| PT107568B (pt) * | 2014-03-31 | 2018-11-05 | Hovione Farm S A | Processo de secagem por atomização para a produção de pós com propriedades melhoradas. |
| PT3131582T (pt) | 2014-04-15 | 2018-10-08 | Vertex Pharma | Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística |
| US9861611B2 (en) | 2014-09-18 | 2018-01-09 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same |
| US20170360791A1 (en) * | 2014-12-04 | 2017-12-21 | Astex Pharmaceuticals, Inc. | Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs |
| KR102579876B1 (ko) | 2016-02-22 | 2023-09-18 | 삼성전자주식회사 | 반도체 패키지 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
| WO2018159852A1 (ja) * | 2017-03-03 | 2018-09-07 | 三栄源エフ・エフ・アイ株式会社 | クルクミン含有製剤 |
| WO2018222172A1 (en) * | 2017-05-30 | 2018-12-06 | Taigen Biotechnology Co., Ltd. | Solid dispersion formulation |
| CA3153745C (en) | 2017-08-04 | 2024-01-02 | ZoomEssence, Inc. | Ultrahigh efficiency spray drying apparatus and process |
| US10155234B1 (en) * | 2017-08-04 | 2018-12-18 | ZoomEssence, Inc. | Ultrahigh efficiency spray drying apparatus and process |
| US10486173B2 (en) | 2017-08-04 | 2019-11-26 | ZoomEssence, Inc. | Ultrahigh efficiency spray drying apparatus and process |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| US10569244B2 (en) | 2018-04-28 | 2020-02-25 | ZoomEssence, Inc. | Low temperature spray drying of carrier-free compositions |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| CN115968292A (zh) | 2020-07-24 | 2023-04-14 | 隆萨本德公司 | 含乙酸的api过饱和溶液的喷雾干燥 |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| CN116234537A (zh) | 2020-10-02 | 2023-06-06 | 隆萨本德公司 | 作为碱性药物的喷雾干燥中的加工助剂的醋酸 |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4479062A1 (en) * | 2022-02-18 | 2024-12-25 | Viking Therapeutics, Inc. | FORMES POSOLOGIQUES ORALES DE L'AGONISTE DE TRß, VK2809, POUR LE TRAITEMENT DE TROUBLES HÉPATIQUES, ET PROCÉDÉS DE PRÉPARATION DE CELLES-CI |
| TWI878935B (zh) * | 2022-06-27 | 2025-04-01 | 太景生物科技股份有限公司 | 包含帽依賴性核酸內切酶抑制劑的藥物組合物 |
| US20250177287A1 (en) * | 2023-12-01 | 2025-06-05 | Serán BioScience, LLC | Methods and systems for injectable formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0570636A (ja) * | 1991-09-17 | 1993-03-23 | Sumitomo Bakelite Co Ltd | 熱可塑性樹脂組成物 |
| ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| EP1027885B1 (en) * | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
| US6223455B1 (en) * | 1999-05-03 | 2001-05-01 | Acusphere, Inc. | Spray drying apparatus and methods of use |
| US20010053791A1 (en) | 2000-03-16 | 2001-12-20 | Babcock Walter C. | Glycogen phosphorylase inhibitor |
| US6800297B2 (en) * | 2000-06-15 | 2004-10-05 | Acusphere, Inc. | Porous COX-2 inhibitor matrices and methods of manufacture thereof |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| DE10055857A1 (de) * | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| WO2003063822A2 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| WO2004101605A1 (en) * | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
| ZA200700030B (en) * | 2004-06-08 | 2009-06-24 | Vertex Pharma | Pharmaceutical compositions |
| PT1993360T (pt) * | 2005-12-28 | 2017-05-25 | Vertex Pharma | Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida |
-
2007
- 2007-03-19 GE GEAP200710941A patent/GEP20125378B/en unknown
- 2007-03-19 EP EP07758806A patent/EP2001497A4/en not_active Withdrawn
- 2007-03-19 EA EA200802008A patent/EA018811B1/ru not_active IP Right Cessation
- 2007-03-19 CA CA002646335A patent/CA2646335A1/en not_active Abandoned
- 2007-03-19 TW TW102143937A patent/TW201414469A/zh unknown
- 2007-03-19 SG SG201101683-9A patent/SG170087A1/en unknown
- 2007-03-19 KR KR1020147022986A patent/KR20140107691A/ko not_active Ceased
- 2007-03-19 US US11/687,779 patent/US20070218012A1/en not_active Abandoned
- 2007-03-19 MX MX2008011976A patent/MX2008011976A/es active IP Right Grant
- 2007-03-19 TW TW096109377A patent/TWI428125B/zh not_active IP Right Cessation
- 2007-03-19 WO PCT/US2007/064294 patent/WO2007109605A2/en not_active Ceased
- 2007-03-19 RS RSP-2009/0406A patent/RS20090406A/sr unknown
- 2007-03-19 KR KR1020087025510A patent/KR20090025187A/ko not_active Abandoned
- 2007-03-19 AU AU2007226984A patent/AU2007226984B2/en not_active Ceased
- 2007-03-19 NZ NZ571934A patent/NZ571934A/en not_active IP Right Cessation
- 2007-03-19 JP JP2009501679A patent/JP2009530416A/ja not_active Withdrawn
- 2007-03-19 CN CN2013101589038A patent/CN103272234A/zh active Pending
- 2007-03-19 BR BRPI0708957-0A patent/BRPI0708957A2/pt not_active IP Right Cessation
- 2007-03-20 AR ARP070101121A patent/AR063468A1/es unknown
- 2007-03-20 UY UY30225A patent/UY30225A1/es unknown
- 2007-03-20 PE PE2007000308A patent/PE20080170A1/es not_active Application Discontinuation
-
2008
- 2008-09-17 IL IL194176A patent/IL194176A/en not_active IP Right Cessation
- 2008-09-22 EC EC2008008759A patent/ECSP088759A/es unknown
- 2008-10-16 NO NO20084334A patent/NO20084334L/no not_active Application Discontinuation
-
2009
- 2009-06-10 US US12/481,962 patent/US8853152B2/en not_active Expired - Fee Related
-
2013
- 2013-05-21 AU AU2013205948A patent/AU2013205948A1/en not_active Abandoned
- 2013-11-20 JP JP2013240174A patent/JP2014037435A/ja active Pending
-
2014
- 2014-03-04 US US14/196,509 patent/US20140183768A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009530416A5 (enExample) | ||
| EP2755637B1 (en) | Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer | |
| Yadav et al. | Mucoadhesive polymers: means of improving the mucoadhesive properties of drug delivery system | |
| EP3076951B1 (en) | Process for the production of drug formulations for oral administration | |
| Vialpando et al. | Evaluation of three amorphous drug delivery technologies to improve the oral absorption of flubendazole | |
| KR20160104709A (ko) | 난수용성 화합물용 약제학적 조성물 | |
| CN105832678A (zh) | 生物利用度提高的包含难溶性药物的微球及其制备方法 | |
| CA2282906A1 (en) | Stable complexes of poorly soluble compounds | |
| US9114170B2 (en) | Highly loaded amorphous efavirenz composition and process for preparing the same | |
| JP2003534296A (ja) | 溶出性の改善されたプランルカスト固体分散系及びその製造方法 | |
| TWI243063B (en) | Orally administrable nifedipine pellet and process for the preparation thereof | |
| JP2009512699A5 (enExample) | ||
| US20140186427A1 (en) | Orodispersible films for the manufacturing of individualised medicine or for large scale production | |
| JP2009506114A5 (enExample) | ||
| US20040228916A1 (en) | Pharmaceutical solid preparation containing a poorly soluble drug and production process thereof | |
| Alai et al. | A novel nanoparticulate system for sustained delivery of acid-labile lansoprazole | |
| RS52053B (sr) | Proces za pripremanje raspršivanjem osušenih formulacija tmc125 | |
| CN100379406C (zh) | 一种难溶性药物微丸的制备方法及包含该微丸的制剂 | |
| US20060286169A1 (en) | Lipophilic compositions | |
| EP2594257A1 (en) | Orodispersible films for the manufacturing of individualised medicine or for large scale production | |
| CN102100678B (zh) | 伊曲康唑硫酸盐微丸及其制备方法 | |
| JP2021502384A (ja) | 改善された薬物製剤 | |
| JP5443768B2 (ja) | 医薬品球状物 | |
| WO2013169523A1 (en) | Solubility enhanced compositions | |
| US20250387335A1 (en) | Pharmaceutical Compositions, and Preparation and Methods of Use Thereof |